Advanced Search
Contact | Corporate | Help

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

Sponsors:
  • Abbott
  • Genentech
Phases:
  • Phase I
IndicationsAcronym:
  • Solid Tumor
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: ABT-263
  • Drug: gemcitabine
Enrollment:
25

Additional information about NCT00887757.


SourceSolution © 2008-2012